ONTRUZANT is a prescription medicine approved for the treatment of HER2+ breast cancer. It can be used in combination with certain chemotherapy drugs or alone after treatment with chemotherapy. Patients are selected for therapy based on an FDA-approved test for trastuzumab.

ONTRUZANT is a targeted therapy designed to interrupt tumor cell growth in HER2+ breast cancer; ONTRUZANT may stop the HER2 receptors from signaling cancer cells to grow; ONTRUZANT may also be able to identify tumor cells to be destroyed by the immune system

ONTRUZANT is a prescription medicine used to treat: Adjuvant Breast Cancer. ONTRUZANT is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph ...

Here is what you can expect when you first receive ONTRUZANT. ONTRUZANT is given through an intravenous (IV) infusion. A needle with an IV line will be inserted into a vein so the medicine can reach your body.

ONTRUZANT is a prescription medicine used to treat: Adjuvant Breast Cancer. ONTRUZANT is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph ...

The Organon Access Program for ONTRUZANT. The Organon Access Program (OAP) may be able to answer your questions about insurance coverage, co-pay assistance for eligible patients, eligibility determination, and more. You can:

A guide for patients getting started on ONTRUZANT. Not an actual patient. Where can I find . patient support for ONTRUZANT? How is ONTRUZANT given? What is ONTRUZANT? What to expect from . treatment with ONTRUZANT Indications and Important Safety . Information

ONTRUZANT is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one ...